Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc., organized in Maryland, reports beneficial ownership of 3,825,950 shares of Cullinan Therapeutics Inc common stock. This position represents 6.2% of the class as of the reporting date. The firm reports sole voting power and sole dispositive power over all 3,825,950 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and it expressly denies such beneficial ownership.

Key Figures

Shares beneficially owned: 3,825,950 shares Percent of class: 6.2% Sole voting power: 3,825,950 shares +1 more

4 metrics

Shares beneficially owned 3,825,950 shares Beneficial ownership reported by T. Rowe Price Associates for Cullinan Therapeutics common stock

Percent of class 6.2% Percentage of Cullinan Therapeutics common stock class reportedly owned

Sole voting power 3,825,950 shares Shares over which T. Rowe Price Associates has sole power to vote or direct the vote

Sole dispositive power 3,825,950 shares Shares over which T. Rowe Price Associates has sole power to dispose or direct disposition

Key Terms

beneficial owner, sole voting power, sole dispositive power, percent of class

4 terms

beneficial owner financial

"shall not be construed as an admission that Price Associates is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power financial

"Sole Voting Power 3,825,950.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 3,825,950.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: 6.2 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What stake does T. Rowe Price Associates report in Cullinan Therapeutics (CGEM)?

T. Rowe Price Associates reports beneficial ownership of 3,825,950 shares of Cullinan Therapeutics common stock, representing 6.2% of the outstanding class, with sole voting and sole dispositive power over all reported shares.

Does T. Rowe Price Associates have sole or shared voting power over CGEM shares?

T. Rowe Price Associates reports sole voting power over 3,825,950 shares of Cullinan Therapeutics and no shared voting power, indicating it alone can vote or direct the voting of the reported shares.

What dispositive power does T. Rowe Price Associates report over Cullinan Therapeutics (CGEM) stock?

The firm reports sole dispositive power over 3,825,950 shares of Cullinan Therapeutics common stock and no shared dispositive power, meaning it alone can determine how these shares are sold or otherwise disposed of.

Does T. Rowe Price Associates admit beneficial ownership of its CGEM position?

No. T. Rowe Price Associates explicitly states that filing this report shall not be construed as an admission of beneficial ownership of the Cullinan Therapeutics securities and that such beneficial ownership is expressly denied.

What percentage of Cullinan Therapeutics (CGEM) does 3,825,950 shares represent?

The holding of 3,825,950 shares of Cullinan Therapeutics common stock represents 6.2% of the class, according to the ownership information provided by T. Rowe Price Associates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:40 AM Accepted by SEC EDGAR 08/14/2026 - 10:38 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cullinan Therapeutics Inc

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

230031106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 230031106

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,825,950.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,825,950.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,825,950.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cullinan Therapeutics Inc
(b)	Address of issuer's principal executive offices: ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 2142
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 230031106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3825950
(b)	Percent of class: 6.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3825950
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3825950
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026